Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy

Journal for ImmunoTherapy of Cancer 2026 Open access

Read full text
DOI: 10.1136/jitc-2025-013246corr1
Cited by: 0

Abstract

Chen T, Wang Y, Chen X, et al. Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy. J Immunother Cancer 2026;14:e013246. https://doi.org/10.1136/jitc-2025-013246

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses CAR-T cell therapy research

Publication details

Journal / source
Journal for ImmunoTherapy of Cancer
Volume
14
Issue
1
Pages
e013246corr1–e013246corr1
Publication date
1 January 2026
Language
EN